Cansortium Stock Performance
| CNTMF Stock | USD 0.05 0.0006 1.22% |
The firm shows a Beta (market volatility) of -1.39, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Cansortium are expected to decrease by larger amounts. On the other hand, during market turmoil, Cansortium is expected to outperform it. Cansortium right now shows a risk of 9.14%. Please confirm Cansortium maximum drawdown, as well as the relationship between the accumulation distribution and day typical price , to decide if Cansortium will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cansortium has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable primary indicators, Cansortium is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 3.4 M | |
| Total Cashflows From Investing Activities | -22.1 M |
Cansortium |
Cansortium Relative Risk vs. Return Landscape
If you would invest 5.80 in Cansortium on October 23, 2025 and sell it today you would lose (0.96) from holding Cansortium or give up 16.55% of portfolio value over 90 days. Cansortium is currently producing 0.0724% returns and takes up 9.1446% volatility of returns over 90 trading days. Put another way, 82% of traded otc stocks are less volatile than Cansortium, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cansortium Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cansortium's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Cansortium, and traders can use it to determine the average amount a Cansortium's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0079
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | CNTMF |
| Negative Returns |
Based on monthly moving average Cansortium is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cansortium by adding Cansortium to a well-diversified portfolio.
Cansortium Fundamentals Growth
Cansortium OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Cansortium, and Cansortium fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cansortium OTC Stock performance.
| Return On Equity | -0.28 | |||
| Return On Asset | 0.021 | |||
| Profit Margin | (0.29) % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 118.5 M | |||
| Shares Outstanding | 225.38 M | |||
| Price To Book | 0.96 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 65.44 M | |||
| EBITDA | 11.66 M | |||
| Cash And Equivalents | 8.86 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 53.67 M | |||
| Debt To Equity | 1.89 % | |||
| Book Value Per Share | 0.15 X | |||
| Cash Flow From Operations | (5.03 M) | |||
| Earnings Per Share | (0.1) X | |||
| Total Asset | 182.46 M | |||
About Cansortium Performance
By analyzing Cansortium's fundamental ratios, stakeholders can gain valuable insights into Cansortium's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cansortium has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cansortium has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. Cansortium Inc. was incorporated in 2018 and is headquartered in Miami, Florida. Cansortium operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Cansortium performance evaluation
Checking the ongoing alerts about Cansortium for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Cansortium help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cansortium had very high historical volatility over the last 90 days | |
| Cansortium has some characteristics of a very speculative penny stock | |
| Cansortium has high likelihood to experience some financial distress in the next 2 years | |
| Cansortium has accumulated 53.67 M in total debt with debt to equity ratio (D/E) of 1.89, which is about average as compared to similar companies. Cansortium has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Cansortium until it has trouble settling it off, either with new capital or with free cash flow. So, Cansortium's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cansortium sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cansortium to invest in growth at high rates of return. When we think about Cansortium's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 65.44 M. Net Loss for the year was (19.04 M) with profit before overhead, payroll, taxes, and interest of 35.79 M. | |
| Cansortium has accumulated about 8.86 M in cash with (5.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 21.0% of Cansortium shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Engie wins SECI bid for 200MW solar PV-600MWh battery project in India |
- Analyzing Cansortium's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cansortium's stock is overvalued or undervalued compared to its peers.
- Examining Cansortium's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cansortium's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cansortium's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Cansortium's otc stock. These opinions can provide insight into Cansortium's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cansortium OTC Stock analysis
When running Cansortium's price analysis, check to measure Cansortium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cansortium is operating at the current time. Most of Cansortium's value examination focuses on studying past and present price action to predict the probability of Cansortium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cansortium's price. Additionally, you may evaluate how the addition of Cansortium to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |